American Society for Parenteral and Enteral Nutrition (ASPEN), 2023
Annual global conference for interdisciplinary, clinical nutrition leaders, providing the latest in clinical nutrition research, education, and products.
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
Scientific Congresses in Gastroenterology
Selected Data Presentations
Select "Upcoming" to see a list of future scientific congresses in gastroenterology. Select "Past" to review data and presentations from recent congresses. This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas.
Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.
Upcoming & Past Conferences
-
Upcoming
-
Past
Digestive Disease Week (DDW), 2023
Global meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
Professional Society for Health Economics and Outcomes Research (ISPOR), 2023
Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
American Neurogastroenterology and Motility Society (ANMS), 2023
Annual meeting uncovering cutting-edge research ranging from basic neurogastroenterology, translational and clinical aspects of gastrointestinal motility, and functional disorders.
European Society for Clinical Nutrition & Metabolism Congress (ESPEN), 2023
Annual global congress dedicated to clinical nutrition and metabolism, including basic and clinical research, education, and organization of consensus statements about clinical care.
Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2023
Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.
Academy of Managed Care Pharmacy (AMCP), 2023
March 21 - 24, 2023
Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy, offering immersive education sessions and keynote presentations.
European Crohn's and Colitis Organization (ECCO), 2023
March 1 - 4, 2023
Global congress focused on optimizing care for patients with IBD by offering sessions around basic science, traditional medication and clinical discussions.
Crohn's & Colitis Congress (CCC), 2023
January 19 - 21, 2023
Annual conference for a multidisciplinary community of practitioners and researchers focusing on inflammatory bowel disease (IBD) by pairing best practices in clinical care with innovative research.
Advances in Inflammatory Bowel Diseases (AIBD), 2022
December 5 - 7, 2022
An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.
American College of Gastroenterology (ACG), 2022
October 21 - 26, 2022
Premier event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.
- Perspectives, Experiences, and Concerns Among Patients With Short Bowel Syndrome (SBS) and Their Caregivers: Insights From Social Media Platforms
Motegrity® (prucalopride)
- Efficacy and Safety of Prucalopride in Patients with Renal Dysfunction: a post hoc Analysis of Phase 3 and 4 Cinical Trials in Chronic Idiopathic Constipation
Entyvio® (vedolizumab)
- Real-World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Study
- The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update
- Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients with Crohn’s Disease: Results from the ODESSA-CD Study
- [Supplemental Material] Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients with Crohn’s Disease: Results from the ODESSA-CD Study
- Comparison of Surgery Rates in Biologic-Naïve Patients with Crohn’s Disease Who Were Treated with Vedolizumab or Ustekinumab: Findings from SOJOURN
- Baseline Demographics and Disease Characteristics of Patients with Ulcerative Colitis Who Responded to Vedolizumab at Week 6
North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN), 2022
October 12 - 14, 2022
Annual forum for participants to learn about the latest advances in pediatric gastroenterology, hepatology, and nutrition and to discuss current topics in clinical applications.
Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2022
October 11 - 14, 2022
Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.
- [Supplemental Material] Treatment Patterns and Outcomes in Patients with High-Risk or Low-Risk Crohn’s Disease or Ulcerative Colitis: a Retrospective Analysis of Claims Data from a Large US Commercially Insured and Medicare Advantage Population
- Treatment Patterns and Outcomes in Patients with High-Risk or Low-Risk Crohn’s Disease or Ulcerative Colitis: a Retrospective Analysis of Claims Data from a Large US Commercially Insured and Medicare Advantage Population
United European Gastroenterology Week (UEGW), 2022
October 8 - 11, 2022
Global congress for researchers from around the world to present their findings on gastroenterology and digestive health.
Entyvio® (vedolizumab)
- Long-term Outcomes of Vedolizumab in Inflammatory Bowel Disease: The Swedish Prospective Multicentre SVEAH Extension Study
- Linking Location Specific Gene Expression Patterns to Potential Vedolizumab Outcomes in Crohn’s Disease Patients
- Understanding the Impact of Previous TNF-α Inhibitors on Vedolizumab Response in Patients with Ulcerative Colitis and Crohn’s disease Using Systematic Review and Gene Expression Data
- Mucosal Healing With Vedolizumab in Inflammatory Bowel Disease: Evidence From EARNEST, a Randomised, Double-Blind, Placebo-Controlled Trial in Chronic Pouchitis
European Society for Clinical Nutrition & Metabolism Congress (ESPEN), 2022
September 3 - 6, 2022
Annual global congress dedicated to clinical nutrition and metabolism, including basic and clinical research, education, and organization of consensus statements about clinical care.
Federation of Clinical Immunology Societies (FOCIS), 2022
June 21 - 24, 2022
Annual meeting with a unique focus on translational immunology and interdisciplinary approaches to understanding disease and identifying new therapeutic approaches.
Digestive Disease Week (DDW), 2022
May 21 - 24, 2022
Global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
- An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis
- High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
Motegrity® (prucalopride)
- A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation
- Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age: a post hoc analysis of phase 3 and 4 clinical trials
Entyvio® (vedolizumab)
- A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
- A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment [Supplemental Material]
- Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-Line Biologic Treatments: Findings From ROTARY
- Early Modification of Inflammatory Burden Through Treatment With Vedolizumab or Adalimumab is Predictive of Long-Term Treatment Success in Patients With Ulcerative Colitis From the VARSITY Study
- Early Versus Delayed Initiation of Vedolizumab in Ulcerative Colitis: Real World Treatment Response (RALEE)
- Effects of anti-integrin a4b7 on colon immune cells
- Identifying the Most Effective Treatment Algorithm for Therapies to Treat Moderate to Severe Ulcerative Colitis
- Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A
- Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings From ROTARY Part A [Supplemental Material]
- Uptake and Patterns of Influenza Vaccine Administration Among Patients With Inflammatory Bowel Disease: a Claims-Based Analysis
Academy of Managed Care Pharmacy (AMCP), 2022
March 29 - April 1, 2022
Large assembly of pharmacy and health care professionals dedicated to the issues of managed care pharmacy offering immersive education sessions and keynote presentations.
Motegrity® (prucalopride)
Inflammatory Bowel Disease Horizons (IBD Horizons), 2022
March 5, 2022
Focused on the education related to diagnosis, management and advancement of IBD providing accredited symposia where access to IBD specialists and centers is limited.
European Crohn's and Colitis Organization (ECCO), 2022
February 16 - 19, 2022
Global congress focused on optimizing care for patients with IBD by offering sessions around basic science, traditional medication and clinical discussions.
- An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis
- Development and validation of a 13 item short version of the IBD self efficacy scale
- Real-world characteristics and complications of patients with ulcerative colitis receiving conventional therapy in the public healthcare system in Brazil
Entyvio® (vedolizumab)
- A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment
- A Single-Cell Approach Reveals Immune Cell Dynamics in Inflammatory Bowel Disease (IBD) and Highlights Association of CD8 Intraepithelial Lymphocytes (IELs) With Response to Vedolizumab Treatment [Supplemental Material]
- Early Modification of Inflammatory Burden Through Treatment With Vedolizumab or Adalimumab is Predictive of Long-Term Treatment Success in Patients With Ulcerative Colitis From the VARSITY Study
- Mucosal eosinophil abundance in non-inflamed colonic tissue predicts response to vedolizumab induction therapy in inflammatory bowel disease
- Predictors of Pancreatitis Among Patients With Inflammatory Bowel Disease Treated With Vedolizumab: Observation From a Large Global Safety Database
- Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment
TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. MEDCONNECT™ is a trademark of Takeda Pharmaceuticals U.S.A., Inc.
©2023 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
Welcome to U.S. Medical Affairs at Takeda
This site is intended only for healthcare professionals registered to practice in the U.S. and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. The information is not intended as medical advice and may be incomplete. This resource may include information that has not been approved by the U.S. Food and Drug Administration (FDA). Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional.
Choose an option that describes you:
By clicking on this option, I certify that I am a U.S. healthcare professional.
Select a product and enter keywords to search for specific product information
Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.